Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02951767 · ClinicalTrials.gov registry record · Phase 2
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1)
A Phase 2 study of Bladder Cancer, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 119
- Enrollment target
- 20
- Study locations
NCT02951767 is a Phase 2 study of Bladder Cancer that has completed, run by Hoffmann-La Roche. The registered enrollment target is 119 participants, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT02951767, a Phase 2 study of Bladder Cancer, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 119 participants
- Enrollment target
- 20
- Study locations
Study Summary
This Phase II, single-arm study is designed to evaluate the effect of atezolizumab treatment in participants with locally advanced or metastatic urothelial bladder cancer. Participants will be enrolled into 1 of 2 cohorts. Cohort 1 (reported here) will consist of participants who are treatment-naïve and ineligible for cisplatin-containing chemotherapy. Cohort 2 will contain participants who have progressed during or following a prior platinum-based chemotherapy regimen. The results of the second cohort are reported separately (NCT02108652). Participants in both cohorts will be given a 1200 milligrams (mg) intravenous (IV) dose of atezolizumab on Day 1 of 21-day cycles. Treatment of participants in Cohort 1 will continue until disease progression per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or unmanageable toxicity. Treatment of participants in Cohort 2 will continue until loss of clinical benefit or unmanageable toxicity.
Conditions Studied
Interventions
- DRUG Atezolizumab
Study Locations (20)
California
- UCLA - Los Angeles
- The Angeles Clinic and Research Institute - W LA Office - Los Angeles
- USC Norris Cancer Center - Los Angeles
- UCSF - San Francisco
- Kaiser Permanente - San Marcos - San Marcos
- Stanford Cancer Center - Stanford
- Kaiser Permanente; Oncology Clinical Trials - Vallejo
Arizona
- Pinnacle Oncology Hematology - Scottsdale
- Arizona Oncology - HOPE Wilmot - Tucson
Colorado
- Rocky Mountain Cancer Center - Aurora - Aurora
- University Of Colorado - Aurora
Connecticut
- University of Connecticut Health Center - Farmington
- Yale Cancer Center ; Medical Oncology - New Haven
Illinois
- University of Chicago; Hematology/Oncology - Chicago
- Ingalls Memorial Hospital - Harvey
Alabama
- University of Alabama At Birmingham - Birmingham
District of Columbia
- Georgetown University Medical Center Lombardi Cancer Center - Washington D.C.
Florida
- Mayo Clinic Cancer Center - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2014-05-31 |
| Est. Completion | 2023-02-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02951767
The ClinicalTrials.gov registry entry for NCT02951767 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bladder Cancer appearing as the primary indexed condition, and to 1 intervention - of which Atezolizumab is the first listed.
NCT02951767 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT02951767 about?
NCT02951767 is a clinical study titled "A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1)". This Phase II, single-arm study is designed to evaluate the effect of atezolizumab treatment in participants with locally advanced or metastatic urothelial bladder cancer. Participants will be enrolled into 1 of 2 cohorts. Cohort 1 (reported here) will consist of participants who are treatment-naïve...
What is the current status of trial NCT02951767?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 119 participants. The study started on 2014-05-31. Estimated completion is 2023-02-28.
What conditions does trial NCT02951767 study?
This clinical trial studies the following conditions: Bladder Cancer.
What interventions are being tested in trial NCT02951767?
The interventions under investigation include: Atezolizumab (DRUG).
Who is sponsoring clinical trial NCT02951767?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02951767 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Telehealth Intervention for Ostomy Self-Management
RECRUITING · Phase 2
-
Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
RECRUITING · Phase 2
-
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
RECRUITING · Phase 2
-
Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)
RECRUITING · Phase 2
-
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
RECRUITING · Phase 2
-
Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.